Skip to content

Topiramate in skin picking disorder

A pilot study of the use of topiramate in skin picking disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15791118
Enrollment
20
Registered
2016-12-23
Start date
2013-12-01
Completion date
Unknown
Last updated
2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin picking disorder Mental and Behavioural Disorders

Interventions

Patients with skin picking will be enrolled in the study based upon diagnostic criteria by DSM 5 and followed for a 12-week period in an open label method. Patients will be started on 25mg topiramate

Sponsors

Jafferany Psychiatric Services
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Recurrent skin picking resulting in skin lesions 2. Repeated attempts to decrease or stop skin picking 3. The skin picking causes clinically significant distress or impairment in social, occupational, or other important areas of functioning 4. The skin picking is not attributable to the physiological effects of a substance/another medical condition 5. The skin picking is not better explained by symptoms of another mental disorder 6. Age 18-60 years

Exclusion criteria

Exclusion criteria: 1. Chronic unstable medical illness 2. Pregnancy or lactation 3. Being on other psychotropic medications 4. Current substance abuse 5. Psychotherapy in the last six weeks prior to commencing the study

Design outcomes

Primary

MeasureTime frame
Mean time spent picking per day, measured using participant diaries at 2, 4, 6, 8 and 12 weeks

Secondary

MeasureTime frame
1. Skin picking, obsessions and compulsions are measured using SPS-Y-BCOS at 2, 4, 6, 8 and 12 weeks 2. Skin picking frequency is measured using the skin picking scale at 2, 4, 6, 8 and 12 weeks 3. Anxiety is measured using the Beck anxiety inventory at 2, 4, 6, 8 and 12 weeks 4. Depression is measured using the Beck depression inventory at 2, 4, 6, 8 and 12 weeks 5. Severity is measured using the CGI-severity at 2, 4, 6, 8 and 12 weeks 6. Improvement in clinical condition is measured using the CGI-improvement at 2, 4, 6, 8 and 12 weeks

Countries

Pakistan, United States of America

Contacts

Public ContactMohammad Jafferany
info@drjaff.com+1 (0)989 790 5990

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026